--- title: "Unicycive Therapeutics (UNCY) news: reverse split" url: "https://aibio.space/companies/unicycive-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "UNCY reverse split and class action news: Unicycive regains Nasdaq minimum bid price compliance after reverse split. Unicycive Therapeutics, Inc." --- UNCY Unicycive Therapeutics, Inc. NASDAQ · United States # Unicycive Therapeutics (UNCY) news UNCY reverse split and class action news Legal · 2026-09-28 ## [Unicycive discloses another securities class action over its OLC application](https://aibio.space/news/unicycive-discloses-another-securities-class-action-olc-application/) Unicycive disclosed in an 8-K dated September 28, 2026 that a second securities class action was filed on September 3, 2026 against the company and certain of its officers over its oxylanthanum carbonate application. An earlier class action and two derivative suits are pending in the same federal court. ## Latest Unicycive Therapeutics news 1. 2025-08-18 Legal [Unicycive discloses securities class action over oxylanthanum carbonate statements](https://aibio.space/news/unicycive-discloses-securities-class-action-oxylanthanum-carbonate/) Unicycive said a securities class action was filed in the Northern District of California against the company and certain of its officers, who are not named. The suit concerns statements about its oxylanthanum carbonate application. The company calls the claims meritless. 2. 2025-07-08 Listings [Unicycive regains Nasdaq minimum bid price compliance after reverse split](https://aibio.space/news/unicycive-regains-nasdaq-minimum-bid-price-compliance-after-reverse/) Nasdaq confirmed on July 7, 2025 that Unicycive's shares had averaged at least $1.00 after a 1:10 reverse stock split took effect on June 20, 2025. The release does not say what the FDA has done on the company's lead candidate, which had a PDUFA date of June 28, 2025. ## Unicycive Therapeutics at a glance - **Ticker**: UNCY - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $61.4 million ### Related companies - [Rocket Pharmaceuticals](https://aibio.space/companies/rocket-pharmaceuticals/) NASDAQ: RCKT - [Vincerx Pharma](https://aibio.space/companies/vincerx-pharma/) OTC: VINC - [Dyne Therapeutics](https://aibio.space/companies/dyne-therapeutics/) NASDAQ: DYN - [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) NASDAQ: KYTX - [Vor Biopharma](https://aibio.space/companies/vor-biopharma/) NASDAQ: VOR - [Armata Pharmaceuticals](https://aibio.space/companies/armata-pharmaceuticals/) AMEX: ARMP - [Trevi Therapeutics](https://aibio.space/companies/trevi-therapeutics/) NASDAQ: TRVI - [BridgeBio Pharma](https://aibio.space/companies/bridgebio-pharma/) NASDAQ: BBIO ### Also on NASDAQ - [Annexon](https://aibio.space/companies/annexon/) ANNX - [Biomea Fusion](https://aibio.space/companies/biomea-fusion/) BMEA - [Century Therapeutics](https://aibio.space/companies/century-therapeutics/) IPSC - [Ionis Pharmaceuticals](https://aibio.space/companies/ionis-pharmaceuticals/) IONS - [Exicure](https://aibio.space/companies/exicure/) XCUR - [LENZ Therapeutics](https://aibio.space/companies/lenz-therapeutics/) LENZ ## What Unicycive Therapeutics does Unicycive Therapeutics is a clinical-stage biotechnology company focused on kidney disease. Its business model is to license technologies and drugs and develop them toward approval, first in the U.S., before partnering with global biopharmaceutical companies in the rest of the world. Its two programs are oxylanthanum carbonate, a next-generation phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for acute kidney injury. Oxylanthanum carbonate uses nanoparticle technology and is intended to be swallowed whole, which the company says could reduce pill burden. The company received a Complete Response Letter in June 2025 that cited a third-party manufacturing vendor for deficiencies, resubmitted its NDA in December 2025, and holds a PDUFA target action date of June 29, 2026. UNI-494 is described as a potential first-in-class drug for acute kidney injury. The two licensed programs came from Spectrum Pharmaceuticals and Sphaera Pharma. | Product or program | What it is | Stage | |---|---|---| | Oxylanthanum carbonate (OLC) | Next-generation phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis | NDA resubmitted to the FDA; PDUFA target action date June 29, 2026 | | UNI-494 | Novel drug candidate for the treatment of acute kidney injury | Phase I study in healthy volunteers completed in 2024 | Summarised from the company's [10-K filed Mar 30, 2026](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm). ## Unicycive Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$9.1 million](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/) | [$20.0 million](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/) | | Net income (loss) | [-$26.6 million](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/) | [-$36.7 million](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/) | | Cash from operations | [-$31.3 million](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/) | [-$28.6 million](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/) | | Cash and equivalents | [$29.2 million](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/) | [$26.1 million](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/) | | Short-term investments | [$12.1 million](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/) | | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $44.2 million, plus short-term investments of $17.2 million, $61.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Unicycive Therapeutics Did Unicycive Therapeutics do a reverse stock split? Our latest story on this, dated Jul 8, 2025: "Unicycive regains Nasdaq minimum bid price compliance after reverse split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/unicycive-regains-nasdaq-minimum-bid-price-compliance-after-reverse/). Is there a class action against Unicycive Therapeutics? Our latest story on this, dated Sep 28, 2026: "Unicycive discloses another securities class action over its OLC application". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/unicycive-discloses-another-securities-class-action-olc-application/). What is the ticker symbol of Unicycive Therapeutics? Unicycive Therapeutics, Inc. trades under the ticker UNCY on NASDAQ. Where is Unicycive Therapeutics listed? Unicycive Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Unicycive Therapeutics? The SEC Central Index Key (CIK) for Unicycive Therapeutics, Inc. is 1766140. Its filings are on SEC EDGAR. How many shares does Unicycive Therapeutics have outstanding? 27,855,257 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Unicycive Therapeutics listed under? Our directory records Unicycive Therapeutics, Inc. under United States. What does Unicycive Therapeutics do? Our directory classifies Unicycive Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Unicycive Therapeutics? The ISIN recorded for Unicycive Therapeutics, Inc. is US90466Y2028. Does aibio.space cover Unicycive Therapeutics? aibio.space lists Unicycive Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Unicycive Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Unicycive Therapeutics develop? Unicycive Therapeutics is a clinical-stage biotechnology company focused on kidney disease. Its business model is to license technologies and drugs and develop them toward approval, first in the U.S., before partnering with global biopharmaceutical companies in the rest of the world. What is Oxylanthanum carbonate (OLC) from Unicycive Therapeutics? Oxylanthanum carbonate (OLC): Next-generation phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis Stage: NDA resubmitted to the FDA; PDUFA target action date June 29, 2026. What is UNI-494 from Unicycive Therapeutics? UNI-494: Novel drug candidate for the treatment of acute kidney injury Stage: Phase I study in healthy volunteers completed in 2024. Is Unicycive Therapeutics profitable? Unicycive Therapeutics, Inc. reported a net loss of $26.6 million for the fiscal year ended Dec 31, 2025, and used $31.3 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Unicycive Therapeutics Members talk about Unicycive Therapeutics (UNCY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Unicycive Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-09-28 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390026104076/ea0306890-8k_unicycive.htm) 2. 2026-06-05 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390026065828/ea0291976-8k_unicycive.htm) 3. 2026-03-30 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm) 4. 2025-11-14 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390025111042/ea0265675-424b5_unicycive.htm) 5. 2025-08-18 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390025077937/ea0253753-8k_unicycive.htm) 6. 2025-07-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390025061936/ea024832201ex99-1_unicycive.htm) 7. 2025-06-20 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390025056188/ea024629901ex99-1_unicycive.htm) 8. 2025-06-13 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390025054305/ea0245641-424b5_unicy.htm) 9. 2025-06-09 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390025052413/ea0245071-8k_unicycive.htm) 10. 2025-05-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390025042943/ea0240849-10q_unicycive.htm) 11. 2025-04-30 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390025037613/ea0239611-def14a_unicycive.htm) 12. 2025-04-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390025033307/ea0238584-pre14a_unicycive.htm) 13. 2025-01-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1766140/000121390025001640/ea0227071-8k_unicycive.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:UNCY on TradingView](https://www.tradingview.com/symbols/NASDAQ-UNCY/). ## SEC filings and registration - **SEC name**: Unicycive Therapeutics, Inc. - **CIK**: 1766140 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: UNCY (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA, 94040 - **Phone**: 650-384-0642 - **Shares outstanding**: 27,855,257 as of 2026-08-12 (10-Q filed 2026-08-12) - **Former names**: Unicycive Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1766140/000121390026104314/ea0306967-8k_unicycive.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1766140/000121390026104076/ea0306890-8k_unicycive.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/ea0301699-8k_unicycive.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1766140/000121390026074678/ea0296892-8k_unicycive.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1766140/000121390026070316/ea0295382-8k_unicycive.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1766140/000121390026065828/ea0291976-8k_unicycive.htm) filed 2026-06-05 - [S-3](https://www.sec.gov/Archives/edgar/data/1766140/000121390026065819/ea0291789-s3_unicycive.htm) filed 2026-06-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001766140), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Unicycive Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker UNCY, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Unicycive Therapeutics, Inc. - **Ticker**: UNCY - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US90466Y2028 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-UNCY/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/unicycive-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Unicycive Therapeutics (UNCY) news: reverse split", 2026-10-31, https://aibio.space/companies/unicycive-therapeutics/